Key Points
- The U.S. FDA has mandated that all GLP-1 weight-loss and diabetes drugs, including Ozempic and Wegovy, carry warnings about the risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), known
- The regulatory action resonates strongly in South Korea, where health authorities disclosed that a suspected case of NAION linked to GLP-1 medication was reported domestically in late 2024.
- With South Korea's high public interest in diet trends and lifestyle medicine, international safety warnings directly influence domestic consumer awareness and regulatory scrutiny.
Summary The global sensation surrounding GLP-1 weight-loss and diabetes treatments—popularized by blockbuster brand names such as Ozempic and Wegovy—has encountered a significant regulatory milestone. The U.S. Food and Drug Administration (FDA) has mandated that pharmaceutical companies update the warning and precautions labels on all GLP-1 receptor agonist medications to include the potential risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), a condition commonly known as an "eye stroke."
NAION occurs when blood flow to the optic nerve is disrupted, leading to sudden vision impairment or irreversible blindness, making it the second most frequent cause of optic nerve-related blindness following glaucoma. While the exact biological mechanism linking semaglutide and other GLP-1 medications to optic nerve damage remains unclear, the FDA made its decision after evaluating clinical trial data and multiple observational studies indicating a rare but elevated incidence among patients on these medications. European regulatory bodies, including the European Medicines Agency (EMA), previously classified NAION as a very rare side effect in mid-2025, recommending warning updates across Europe.
In South Korea, where the demand for modern weight-loss and lifestyle wellness treatments has soared in tandem with international trends, health authorities have been monitoring these developments closely. In an audit before the National Assembly's Health and Welfare Committee, Korea's Minister of Food and Drug Safety, Oh Yu-kyoung, disclosed that South Korea documented a suspected case of NAION-related visual impairment linked to GLP-1 weight-loss medications in December 2024. As weight-loss injectables become increasingly embedded in contemporary urban lifestyle culture and healthcare discussions in Korea, global safety updates directly resonate with domestic consumers and healthcare professionals who are navigating the benefits and emerging risks of next-generation obesity therapies.
Sponsored · Ad